Applicant: Hiroyuki Tsunoda et al. Attorney's Docket No.: 14875-162US1/C1-A0311P-US

Serial No.: To Be Assigned

Filed: Herewith Page: 3 of 8

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (Original) A DNA construct, wherein a mammalian β -actin promoter is operably linked to an enhancer.
- 2. (Currently Amended) The DNA construct of claim 1, wherein the enhancer is <u>derived</u> from Cytomegalovirus (CMV).
- 3. (Original) The DNA construct of claim 1, wherein the enhancer is Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE).
- 4. (Currently Amended) The DNA construct of any one of claims 1 to 3 claim 1, wherein the mammalian β -actin promoter is a rodent β -actin promoter.
- 5. (Original) The DNA construct of claim 2, wherein the CMV enhancer comprises the nucleotide sequence shown in SEQ ID NO: 4 and the mammalian β -actin promoter comprises the nucleotide sequence shown in SEQ ID NO: 2.
- 6. (Original) The DNA construct of claim 3, wherein the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) comprises the nucleotide sequence shown in SEQ ID NO: 3 and the mammalian β -actin promoter comprises the nucleotide sequence shown in SEQ ID NO: 2.

. Applicant: Hiroyuki Tsunoda et al. Attorney's Docket No.: 14875-162US1 / C1-A0311P-US

Serial No.: To Be Assigned

Filed: Herewith Page: 4 of 8

7. (Currently Amended) A vector comprising the DNA construct of any one of claims 1 to 6 claim 1.

- 8. (Original) The vector of claim 7, comprising a DNA having a desired DNA operably linked downstream of the mammalian β -actin promoter.
- 9. (Currently Amended) The vector of claim 7-or-8, comprising and capable of expressing a DNA encoding a transactivator.
 - 10. (Original) The vector of claim 9, wherein the transactivator is an oncogene product.
 - 11. (Original) The vector of claim 10, wherein the oncogene product is Ras.
- 12. (Currently Amended) The vector of any one of claims 8 to 11 claim 8, wherein the desired DNA encodes a desired protein.
- 13. (Currently Amended) A cell comprising the vector of any one of claims 8 to 12 claim 8.
- 14. (Currently Amended) A cell comprising the vector of any one of claims 8 to 12 claim 8, wherein the oncogene is activated.
- 15. (Original) The cell of claim 14, into which the vector comprising the gene encoding the transactivator is introduced.
 - 16. (Original) The cell of claim 14, which is a transformed cell.

Applicant: Hiroyuki Tsunoda et al. Attorney's Docket No.: 14875-162US1 / C1-A0311P-US

Serial No.: To Be Assigned

Filed: Herewith Page: 5 of 8

17. (Currently Amended) The cell of any one of claims 13 to 16 claim 13, which is a mammalian cell.

- 18. (Original) The cell of claim 17, which is a rodent cell.
- 19. (Currently Amended) The cell of any one of claims 13 to 18 claim 13, which is derived from the same animal order as that from which the β -actin promoter is derived.
- 20. (Original) The cell of claim 19, which is derived from the same animal species as that from which the β -actin promoter is derived.
- 21. (Currently Amended) A non-human transgenic animal into which the vector according to any one of claims 8 to 12 claim 8 has been introduced.
- 22. (Currently Amended) A totipotent cell into which the vector of any one of claims 8 to 12 claim 8 is introduced.
- 23. (Original) A method for producing a desired protein, which comprises culturing a cell comprising the vector of claim 12; and harvesting the expressed protein from the cultured cell or medium.
- 24. (Original) The method of claim 23, which comprises adding a transactivator to the medium.
- 25. (Currently Amended) A method for expressing a desired DNA in a host cell, which comprises introducing the vector of any one of claims 8 to 12 claim 8 into the host cell derived from the same animal order as that from which the β-actin promoter in the vector is derived.

Applicant: Hiroyuki Tsunoda et al. Attorney's Docket No.: 14875-162US1 / C1-A0311P-US

Serial No.: To Be Assigned

Filed: Herewith Page: 6 of 8

26. (Currently Amended) A method for expressing a desired DNA in a host cell, which comprises introducing the vector of any one of claims 8 to 12 into a host cell derived from the same animal species as that from which the β-actin promoter in the vector is derived. The method of claim 25, wherein the host cell is derived from the same animal species as that from which the β-actin promoter in the vector is derived.

- 27. (Original) A method for expressing a desired DNA in a host cell, which comprises introducing the vector of claim 8 and a vector comprising and capable of expressing a DNA encoding a transactivator into a host cell which is derived from the same species as that from which the β-actin promoter in the vector of claim 8 is derived.
- 28. (Currently Amended) The method of any one of claims 25 to 27 claim 25, wherein the host cell is a mammalian cell.
- 29. (Currently Amended) The method of any one of claims 25 to 27 claim 25, wherein the host cell is a rodent cell.
- 30. (Currently Amended) A method for increasing the expression level of a desired DNA in a host cell, which comprises inserting upstream of the desired DNA a β -actin promoter derived from the same animal order as that from which the host cell is derived.
- 31. (Currently Amended) A-method for increasing the expression level of a desired DNA, which comprises inserting upstream of the desired DNA a β-actin promoter derived from the same animal species as that from the host cell is derived. The method of claim 30, wherein the β-actin promoter is derived from the same animal species as that from which the host cell is derived.

Applicant: Hiroyuki Tsunoda et al. Attorney's Docket No.: 14875-162US1 / C1-A0311P-US

Serial No.: To Be Assigned

Filed: Herewith Page: 7 of 8

32. (Currently Amended) The method of claim 30-or 31, which further comprises inserting an enhancer.

- 33. (Original) The method of claim 32, wherein the enhancer is Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE).
 - 34. (Original) The method of claim 32, wherein the enhancer is a CMV enhancer.
- 35. (Currently Amended) The method of any one of claims 30 to 34 claim 30, which comprises inserting a gene encoding a transactivator gene.
- 36. (Currently Amended) The method of any one of claims 30 to 35 claim 30, wherein the host cell is a mammalian cell.
- 37. (Currently Amended) The method of any one of claims 30 to 35 claim 30, wherein the host cell is a rodent cell.
 - 38. (New) The method of claim 27, wherein the host cell is a mammalian cell.
 - 39. (New) The method of claim 27, wherein the host cell is a rodent cell.